PBAC's latest decision on Epoprostenol: Recommended with restriction (2016). Considered for Long-term treatment via continuous intravenous infusion of pulmonary arterial hypertension (idiopathic, familial, or associated with scleroderma spectrum of diseases) in WHO functional Class III or Class IV patients.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2014
Submissions
2
2014 → 2016
Eligible population
WHO Functional Class III or Class IV patients with idiopathic pulmonary arterial hypertension, anorexigen-induced PAH, hereditable PAH, or PAH secondary to connective tissue disease, who have not received prior PBS-subsidised treatment with a PAH agent and have been assessed by a physician at a designated hospital.
Therapy area
Respiratory
Line of therapy
First-line
Evidence base
Cost-minimisation
Economic model
Cost-minimisation
ICER note
As a minor submission (formulation and supply method change only), no economic comparison was presented.
Submission history
Jul 2014: Recommended · Authority Required
Nov 2016: Recommended with restriction · Authority Required